SIRT1 and Cachexia: Since sirt1 expression was lower in LCM‐treated C2C12 myotubes and NA supplementation was beneficial to maintain sirt1 expression, we used a small molecular activator of sirt1, SRT1720, to directly target sirt1 in order to better define its role in cachexia.